RxDoctor Payments Data

Justin Stano

Rheumatology · Simpsonville, SCNPI 1386059905

Payments from drug & device makers

$1,025in general payments, 2019–2025

Across 36 payments — averaging $28.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$330
  • GSK$129
  • AbbVie$118
  • UCB, Inc.$110
  • Cardinal Health 110 LLC$100
  • AstraZeneca$56
  • plus $181 from 6 others

What the payments were for

  • Consulting fees$10010%
  • Food & beverage$84682%
  • Education$808%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,025 in reported general payments places this provider in the 25th percentile of 123 rheumatology providers in South Carolina.

See all rheumatology providers in South Carolina

Medicare billing

Part B allowed, 2024
$51,354
Medicare patients
265
Services billed
560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab82$815,574
RinvoqUpadacitinib53$322,814
Enbrel SureclickEtanercept17$123,881
Humira PenAdalimumab17$113,327
Humira(Cf)Adalimumab13$84,594
BenlystaBelimumab12$51,701
Hydroxychloroquine Sulfate439$15,248
MethotrexateMethotrexate Sodium332$8,826
Leflunomide105$3,844
Colchicine34$3,376
Febuxostat12$3,075
Mycophenolate Mofetil39$3,006
Prednisone391$2,151
Pilocarpine Hcl17$2,068
Probenecid-ColchicineProbenecid/Colchicine23$1,717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$118$407,40966 claims
GSKBenlysta$129$51,70112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 123 rheumatology providers in South Carolina.

Other rheumatology in Simpsonville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →